SUMATRAN TABLET 50MG

Product Information

Registration Status: Active

SUMATRAN TABLET 50MG is approved to be sold in Singapore with effective from 2009-06-26. It is marketed by NOVARTIS (SINGAPORE) PTE LTD, with the registration number of SIN13667P.

This product contains Sumatriptan 50mg in the form of TABLET. It is approved for ORAL use.

This product is manufactured by HEXAL AG in GERMANY.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Sumatriptan

Description

A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of migraine disorders. A transdermal patch version of sumatriptan is currently in phase I trials in the U.S. under the code name NP101 (NuPathe).

Indication

For the treatment of migraine attacks with or without aura.

Mechanism of Action

The 5-HT1B and 5-HT1D receptors function as autoreceptors, which inhibit the firing of serotonin neurons and a reduction in the synthesis and release of serotonin upon activation. After sumatriptan binds to these receptors, adenylate cyclase activity is inhibited via regulatory G proteins, incrases intracellular calcium, and affects other intracellular events. This results in vasoconstriction and inhibtion of sensory nociceptive (trigeminal) nerve firing and vasoactive neuropeptide release.

Pharmacokinetics

Absorption
Approximately 15%
Distribution
* 2.7 L/kg [subcutaneous dosing]
Metabolism
Hepatic. In vitro studies with human microsomes suggest that sumatriptan is metabolized by monoamine oxidase (MAO), predominantly the A isoenzyme.
Elimination

Clearance

* 1200 mL/min [Following a 6-mg SC injection]

Toxicity

Symptoms of overdose include convulsions, tremor, paralysis, inactivity, ptosis, erythema of the extremities, abnormal respiration, cyanosis, ataxia, mydriasis, salivation, and lacrimation.

Active Ingredient/Synonyms

(3-[2-(dimethylamino)Ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide | 1-[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide | 3-(2-(dimethylamino)Ethyl)-N-methyl-1H-indole-5-methanesulfonamide | 3-[2-(dimethylamino)Ethyl]-N-methylindole-5-methanesulfonamide | NP101 | Sumatran | Sumatriptan | Sumatriptán | Sumatriptan Succinate | Sumatriptanum | Sumax | triptan | Sumatriptan |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank